• Admin

Should changes made to clinical trials during pandemic be kept?

Many of the alterations made to clinical trial procedures during the COVID-19 pandemic should be implemented in the post-COVID-19 roadmap, according to an article published online July 21 in Cancer Discovery.

Keith T. Flaherty, M.D., from Massachusetts General Hospital Cancer Center in Boston, and colleagues describe changes to cancer clinical trials during the COVID-19 pandemic, which were implemented to preserve potential patient benefit while minimizing risk associated with investigational therapies and COVID-19, and address the incorporation of these changes as part of future trials.

The authors note that the requirement for in-person consent was changed to allow for obtaining signed informed consent remotely; making electronic remote consenting permanent is recommended as part of the post-COVID-19 roadmap.

The requirement to use clinical trial-specific laboratories and imaging was altered to allow use of alternate laboratories and imaging centers